Alternately released double slow release coating multi-functional small-bore artificial blood vessel and preparation method thereof

Abstract

The invention relates to an alternately released double slow release coating multi-functional small-bore artificial blood vessel which comprises an artificial blood vessel, wherein double-layered coatings are sprayed to the inner and outer surfaces of the artificial blood vessel, the inner coating of the double-layered coating is a PTX slow release PDMS coating PTX-PDMS and the outer coating thereof is a biodegraded VEGF gene encapsulated polylactic-hydroxyacetic acid copolymer nano microparticle slow release coating PLGA-NPs. Purposes that VEGF gene transfection expression promotes rapid endothelialization of the inner wall of the blood vessel in an early implanting stage and PTX is continuously released to inhibit follow-up intimal hyperplasia in the later stage are achieved by means of a small-bore PET blood vessel formed by the inner PTX-PDMS coating and the outer VEGF gene encapsulated PLGA-NPs slow release coating, and the multi-functional artificial blood vessel plays a synergistic role between promoting migration, proliferation and maturity of endothelial cells and inhibiting vascular smooth muscle cells of a transmembrane, so that good endothelialization of inner wall of the blood vessel and long-term smoothness after implanting are guaranteed, and the long-term smoothness of the small-bore artificial blood vessel can be obviously improved.

Description

technical field [0001] The invention relates to a medical artificial blood vessel and a preparation method thereof, in particular to a multi-functional small-diameter artificial blood vessel with a time-staggered release double-sustained-release coating and a preparation method thereof. Background technique [0002] According to statistics, there are more than 30 million patients with peripheral vascular occlusive disease (PAD) and more than 1 million patients with end-stage renal disease in China, and the number of patients with end-stage renal disease is increasing by 120,000 every year. In order to save the limbs of PAD patients and maintain the "life access" of patients with end-stage renal disease, vascular reconstruction or establishment of arteriovenous access is the most important treatment, and a large number of patients need to use small-caliber artificial Blood vessels (SDVPs, diameter ≤ 6 cm). However, the current SDVPs lack long-term patency and good biocompati...

AI Technical Summary

Problems solved by technology

These studies have solved the problem of endothelialization of the inner wall of artificial blood vessels to varying degrees. CD34 antibody and VEGF curing are facing problems such as difficult control of endothelial cell proliferation, imperfect slow-release technology, and late anastomotic intimal hyperplasia, especially the latter has yet to be resolved

Images